KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Payables (2016 - 2025)

Historic Payables for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $939.0 million.

  • Regeneron Pharmaceuticals' Payables rose 1893.6% to $939.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $939.0 million, marking a year-over-year increase of 1893.6%. This contributed to the annual value of $939.0 million for FY2025, which is 1893.6% up from last year.
  • Regeneron Pharmaceuticals' Payables amounted to $939.0 million in Q4 2025, which was up 1893.6% from $903.8 million recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Payables ranged from a high of $939.0 million in Q4 2025 and a low of $427.0 million during Q3 2021
  • In the last 5 years, Regeneron Pharmaceuticals' Payables had a median value of $562.8 million in 2021 and averaged $611.1 million.
  • In the last 5 years, Regeneron Pharmaceuticals' Payables crashed by 7468.22% in 2021 and then surged by 8174.14% in 2025.
  • Regeneron Pharmaceuticals' Payables (Quarter) stood at $564.0 million in 2021, then rose by 4.47% to $589.2 million in 2022, then increased by 2.95% to $606.6 million in 2023, then surged by 30.15% to $789.5 million in 2024, then grew by 18.94% to $939.0 million in 2025.
  • Its last three reported values are $939.0 million in Q4 2025, $903.8 million for Q3 2025, and $723.9 million during Q2 2025.